We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Immunoassay Evaluated for Quantitative Measurement of Fecal α1-Antitrypsin

By LabMedica International staff writers
Posted on 09 Aug 2016
Print article
Image: The SPECTRAmax PLUS plate reader (Photo courtesy of Molecular Devices).
Image: The SPECTRAmax PLUS plate reader (Photo courtesy of Molecular Devices).
The measurement of the protease α1-antitrypsin (A1A) in stool specimens can be used to detect the presence of serum proteins in the gastrointestinal tract a sign of protein-losing enteropathy (PLE).

The major causes of PLE can be divided into erosive and non-erosive gastrointestinal disorders, as well as increased central venous pressure or mesenteric lymphatic obstruction and among such disorders are enteritis, Crohn disease, ulcerative colitis, and celiac disease.

Scientists at the Associated Regional and University Pathologists (ARUP) Laboratories (Salt Lake City, UT, USA) used residual stool specimens sent to ARUP laboratories for fecal A1A testing, as well as paired sera and timed stool samples obtained from healthy volunteers. A1A in stool was measured with a polyclonal antibody-based enzyme-linked immunosorbent assay (ELISA). Assay imprecision, analytical sensitivity, linearity, accuracy, analyte stability, and reference intervals were determined.

Stool A1A was measured by using the Human α1-Antitrypsin ELISA (ImmuChrom, Heppenheim, Germany). This assay is a polyclonal immunometric method used for quantifying the A1A extracted from stool. Signals for ELISA plates were quantified with a SPECTRAmax PLUS plate reader (Molecular Devices LLC, Sunnyvale, CA, USA). Reference intervals for stool A1A and A1A clearance were established using timed stool samples and sera collected from 124 healthy volunteers (62 males, 62 females; ages 19–61 years).

The investigators found that the limit of quantification of the ELISA method used was 2.0 ng/mL, and the assay was linear to 85 ng/mL. The mean recovery of A1A added to samples was 108.2% and A1A was stable in stool for a minimum of two days, seven days, and three months at room temperature, 4 °C to 8 °C and −20 °C, respectively. The upper 95th percentile reference limits for A1A in stool and A1A clearance were 0.48 mg/g and 49 mL/day, respectively.

The authors concluded that the ImmuChrom human A1A ELISA demonstrates acceptable performance characteristics for quantifying A1A in stool extracts. Furthermore, this stool ELISA may be used in combination with the Tina-Quant A1A serum assay (Roche Diagnostics, Basel Switzerland) to assess A1A clearance for diagnosing and monitoring PLE. The study was published in the July 2016 issue of the Journal of Applied Laboratory Medicine.

Related Links:
Associated Regional and University Pathologists Laboratories
ImmuChrom
Molecular Devices
Roche Diagnostics
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Multi-Function Pipetting Platform
apricot PP5
New
Community-Acquired Pneumonia Test
RIDA UNITY CAP Bac

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel

Breakthrough Diagnostic Approach to Significantly Improve TB Detection

Tuberculosis (TB) remains the deadliest infectious disease globally, with 10.8 million new cases and 1.25 million deaths reported in 2023. Early detection through effective screening is crucial in identifying TB, preventing its spread, and ultimately working towards its eradication. TB can remain dormant in the body for... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.